Skip to main content

Month: May 2021

Assure Completes Acquisition of Sentry Neuromonitoring and Raises 2021 Procedure Guidance

DENVER, May 03, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (“IONM”), is pleased to announce that it has completed the previously announced acquisition (the “Acquisition”) of all of the assets (the “Acquired Assets”) of Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas. As a result of the closing of the Acquisition, the Company raised its guidance for full-year 2021 total procedures from 14,000 to 17,000. This number represents an anticipated increase in cases of more than 70% compared with 2020 and an increase of 165% since 2019. Assure acquired Sentry, a Joint Commission certified IONM company primarily serving the Greater Houston region. Sentry’s operational footprint also extends...

Continue reading

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2021, and provided business highlights. “Our programs have reached a number of exciting milestones so far this year across our broad portfolio of targeted therapeutics for neurodegenerative diseases,” said Ryan Watts, Ph.D., Denali’s Chief Executive Officer. “We remain focused on advancing our lead clinical programs including DNL310 for Hunter syndrome, DNL151 (BIIB122) in collaboration with Biogen for Parkinson’s disease, and DNL343 for amyotrophic lateral sclerosis (ALS). In addition, based on...

Continue reading

Ideal Power to Host First Quarter 2021 Results Conference Call on Thursday, May 13, 2021 at 4:30 P.M. Eastern Time

AUSTIN, Texas, May 03, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced that management will hold a conference call on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss its results for the first quarter ended March 31, 2021. A press release detailing these results will be issued prior to the call. Ideal Power President and CEO Dan Brdar and CFO Tim Burns will host the conference call, followed by a question-and-answer period. To access the call, please use the following information:Date: Thursday, May 13, 2021 Time: 4:30 p.m. EDT, 1:30 p.m. PDTToll-free dial-in number: 1-866-248-8441International dial-in number: 1-323-289-6581Conference ID:  3477153Please...

Continue reading

Viant to Present at Upcoming Investor Conferences

IRVINE, Calif., May 03, 2021 (GLOBE NEWSWIRE) — Viant Technology Inc. (NASDAQ: DSP), a leading people-based advertising software company, today announced that members of its management team are scheduled to present at upcoming investor conferences. Details for each event are as follows: 16th Annual Needham Virtual Technology & Media ConferenceTuesday, May 18, 2021 at 2:15 pm ET Bank of America Global Technology ConferenceWednesday, June 9, 2021 at 2:30 pm ET The presentations will be webcast live on the investor relations section of Viant’s website at investors.viantinc.com. Replays of the presentations will be available on the website following the completion of each event. About ViantViant® is a leading people-based advertising software company that enables marketers and their agencies to centralize the planning, buying...

Continue reading

Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum

– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM, N.C., May 03, 2021 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the final patient has completed their last Week-12 visit in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206, a topical antiviral gel, for the treatment of molluscum contagiosum (“molluscum”). Topline efficacy and safety results from the B-SIMPLE4 study are targeted to be reported before the end of the second quarter of 2021. “We are incredibly pleased with the progress we have continued to make as we advance our lead program. We remain focused on executing our remaining steps according to plan and reporting topline efficacy...

Continue reading

ARHT Media Provides HoloPresence™ Technology to China JV of Net Dragon Websoft Holdings and China Unicom

JV Announces Demonstration to 100 Schools, 1,000 Classes and 10,000 Learners TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT” or “the Company”) (TSXV:ART), the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, is pleased to announce that it has been the holographic technology supplier to a joint venture in China between Net Dragon Websoft Holdings and China Unicom. Last week this joint venture announced that it is launching the New Infrastructure “5G+Smart Education” Application Demonstration Project. Based on technologies such as 5G, VR, AR, holographic classrooms and ultra-high-definition video, it aims to provide an exemplar of “5G+Smart Education” applications with the participation of a hundred schools, a thousand...

Continue reading

Antares Pharma Announces Poster Presentation at the Pediatric Endocrine Society 2021 Virtual Annual Meeting

EWING, N.J., May 03, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that data highlighting the therapeutic potential of subcutaneous testosterone enanthate in younger hypogonadal populations was presented in a poster presentation at the Pediatric Endocrine Society (PES) 2021 Virtual Annual Meeting on April 30 – May 3, 2021. The poster presentation entitled, “Allometric Scaling of Testosterone Enanthate Pharmacokinetics from Adult Males to Adolescent Hypogonadal Males (30-60 kg) After IM and SC Administration Using Population PK Modeling”, was presented by Maria Vogiatzi, MD*, Professor of Pediatrics and Director, Adrenal and Puberty Center, Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, Philadelphia, PA. Pharmacokinetic...

Continue reading

Milestone Scientific Reports Preliminary Sales Results for Q1 2021; Revenue Increases 61% Over the Same Period Last Year

ROSELAND, N.J., May 03, 2021 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced preliminary financial results for the first quarter of 2021. Arjan Haverhals, President of Milestone Scientific and CEO of Wand Dental Inc., stated, “I am pleased to report that our revenue for the first quarter of 2021 increased more than 61% to $2.9 million versus $1.8 million for the same period last year. We also achieved a strong sequential increase in sales of 32% versus the fourth quarter of 2020. Importantly, we witnessed growth in both our domestic and international revenues. We attribute this improvement to the success of our new dental sales and marketing strategy. At the...

Continue reading

Latin America Fraud Detection and Prevention Market to Reach USD 2,945.3 Million by 2028; Increasing Incidence of Data Fraud to Stimulate Growth: Fortune Business Insights™

Key Companies Covered in Latin America fraud detection and prevention market are IBM Corporation (New York, United States), Uplexis (São Paulo, Brazil), Experian Information Solutions, Inc. (São Paulo, Brazil’s), Accenture PLC (Dublin, Ireland), Tata Communications (Maharashtra, India), Clearsale LLC (Florida, United States), Neoway (São Paulo, Brazil’s), Konduto (São Paulo, Brazil’s), Inovamind (São Paulo, Brazil’s), Único (São Paulo, Brazil’s), Cred Defense (Bebedouro, São Paulo), HS Prevent (São Paulo, Brazil’s) Pune, India, May 03, 2021 (GLOBE NEWSWIRE) — The Latin America fraud detection and prevention market size is expected to gain momentum by reaching USD 2,945.3 million by 2028 while exhibiting a CAGR of 20.0% between 2021 and 2028. Fortune Business Insights, in its latest report, titled “Latin America Fraud Detection...

Continue reading

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021- ALACHUA, Fla. and CAMBRIDGE, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced an encore presentation of previously reported data from the Company’s ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, Assistant Professor at Casey Eye Institute, Oregon Health & Science University, will review the six-month data from the Phase 1/2 XLRP...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.